January 17, 2019 09:06 AM ESTUpdated 09:17 AM
Bioregnum
Opinion

Short sell­er Cit­ron draws fresh blood go­ing af­ter an­oth­er biotech scalp — but can it still cut that deep?

Over the past 3 years, since Cit­ron’s An­drew Left made a name for him­self as the cru­sad­ing an­a­lyst who helped take down Valeant with an …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Trump pledges his sup­port for a change to the IRA long sought by drug­mak­ers

J&J's Du­a­to says 'not tar­iffs, but tax pol­i­cy' is best way to boost US man­u­fac­tur­ing

Sanofi’s Kymab-orig­i­nat­ed in­flam­ma­to­ry drug flunks mid-stage asth­ma tri­al

Phar­ma tar­iffs could leave lit­tle room to hide with sweep­ing probe un­der­way

Leqem­bi wins EU au­tho­riza­tion for some Alzheimer's pa­tients, giv­ing Bio­gen, Ei­sai a boost over Lil­ly

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times